J Eileen Bird

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective
    Natesan Murugesan
    Department of Chemistry, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543 5400, USA
    J Med Chem 46:125-37. 2003
  2. ncbi A platelet target for venous thrombosis? P2Y1 deletion or antagonism protects mice from vena cava thrombosis
    J Eileen Bird
    Department of Thrombosis Biology, Bristol Myers Squibb, 311 Pennington Rocky Hill Road, Pennington, NJ 08534, USA
    J Thromb Thrombolysis 34:199-207. 2012
  3. ncbi Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the Fletcher trait
    J Eileen Bird
    Department of Thrombosis Biology, Bristol Myers Squibb, Pennington, New Jersey 08534, USA
    Thromb Haemost 107:1141-50. 2012
  4. ncbi Is exogenous tissue plasminogen activator necessary for antithrombotic efficacy of an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI) in rats?
    Eileen Bird
    Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey, 08543, United States
    Thromb Res 120:549-58. 2007
  5. ncbi Prediction of the therapeutic index of marketed anti-coagulants and anti-platelet agents by guinea pig models of thrombosis and hemostasis
    J Eileen Bird
    Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543, USA
    Thromb Res 123:146-58. 2008
  6. ncbi Bleeding response induced by anti-thrombotic doses of a phosphoinositide 3-kinase (PI3K)-β inhibitor in mice
    J Eileen Bird
    Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543, USA
    Thromb Res 127:560-4. 2011
  7. ncbi (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
    Saleem Ahmad
    Bristol Myers Squibb Research and Development, P O Box 4000, Princeton, New Jersey 08543, USA
    J Med Chem 51:2722-33. 2008
  8. ncbi Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension
    Mark C Kowala
    Department of Metabolic and Cardiovascular Drug Discovery 025 289, Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    J Pharmacol Exp Ther 309:275-84. 2004
  9. ncbi Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis
    Xinkang Wang
    Department of Thrombosis Biology, Bristol Myers Squibb Company, 311 Pennington Rocky Hill Road, Pennington, NJ 08534, USA
    J Thromb Thrombolysis 23:41-9. 2007

Collaborators

Detail Information

Publications9

  1. ncbi Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective
    Natesan Murugesan
    Department of Chemistry, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543 5400, USA
    J Med Chem 46:125-37. 2003
    ..In rats, intravenous 16a blocks big ET pressor responses with 30-fold greater potency than 1. After oral dosing at 3 micromol/kg, 16a displays enhanced duration relative to 1...
  2. ncbi A platelet target for venous thrombosis? P2Y1 deletion or antagonism protects mice from vena cava thrombosis
    J Eileen Bird
    Department of Thrombosis Biology, Bristol Myers Squibb, 311 Pennington Rocky Hill Road, Pennington, NJ 08534, USA
    J Thromb Thrombolysis 34:199-207. 2012
    ..However as with many antithrombotic agents the benefit comes at the potential price of an increase in provoked bleeding times...
  3. ncbi Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the Fletcher trait
    J Eileen Bird
    Department of Thrombosis Biology, Bristol Myers Squibb, Pennington, New Jersey 08534, USA
    Thromb Haemost 107:1141-50. 2012
    ..Additional support for the significance of the intrinsic pathway in the coagulation cascade is provided, as well as for a potential new anti-thrombotic approach...
  4. ncbi Is exogenous tissue plasminogen activator necessary for antithrombotic efficacy of an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI) in rats?
    Eileen Bird
    Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey, 08543, United States
    Thromb Res 120:549-58. 2007
    ..This study was designed to further explore the importance of exogenous tPA in revealing PCI activity in rat models of venous and arterial thrombosis and provoked bleeding...
  5. ncbi Prediction of the therapeutic index of marketed anti-coagulants and anti-platelet agents by guinea pig models of thrombosis and hemostasis
    J Eileen Bird
    Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543, USA
    Thromb Res 123:146-58. 2008
    ..The goal of the current study was to benchmark representative marketed drugs in thrombosis and hemostasis models in guinea pigs...
  6. ncbi Bleeding response induced by anti-thrombotic doses of a phosphoinositide 3-kinase (PI3K)-β inhibitor in mice
    J Eileen Bird
    Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543, USA
    Thromb Res 127:560-4. 2011
    ..Our goal was to further evaluate potential of a PI3K-β inhibitor as an anti-thrombotic agent by determining the therapeutic index in another species and efficacy model. Reported effects of TGX-221 in rats were also confirmed...
  7. ncbi (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
    Saleem Ahmad
    Bristol Myers Squibb Research and Development, P O Box 4000, Princeton, New Jersey 08543, USA
    J Med Chem 51:2722-33. 2008
    ..Using this discovery pathway, we compared 1b to other marketed statins to demonstrate its outstanding efficacy and safety profile. With the potential to generate an excellent therapeutic window, 1b was advanced into clinical development...
  8. ncbi Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension
    Mark C Kowala
    Department of Metabolic and Cardiovascular Drug Discovery 025 289, Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    J Pharmacol Exp Ther 309:275-84. 2004
    ..Therefore compounds C and D are novel agents for treating a broad spectrum of patients with essential hypertension and other cardiovascular diseases...
  9. ncbi Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis
    Xinkang Wang
    Department of Thrombosis Biology, Bristol Myers Squibb Company, 311 Pennington Rocky Hill Road, Pennington, NJ 08534, USA
    J Thromb Thrombolysis 23:41-9. 2007
    ..The strong ex vivo fibrinolytic activity of TAFI deficiency or TAFIa inhibition by PCI provides a biomarker of TAFIa inhibition that tracks in vivo antithrombotic efficacy...